Trial AIO-HEP-0217 IMMUTACE

Trial Trial design Status In-/Exclusion Therapy Participants Documents Permissions Tumorboards

Trial

Trial acronym

AIO-HEP-0217 IMMUTACE

Full title

A Phase II single-arm, open-label study of transarterial chemoembolization (TACE) in combination with nivolumab performed for intermediate stage hepatocellular carcinoma (HCC)

Responsible organization

2. Med 2. Med Ismaninger Str. 22 81675 München Germany

Indications

Classification	Code	Description
-		Livertumor

Trial design

Phase

Status

Recruitment finished

Votes

Initiiation & lock

Date of lock (planned / actual)

Unknown / Unknown

Therapy

Chemo

Participants

	Function	Prename	Surname	Organization
	Responsible contact	Ursula	Ehmer	2. Med 2. Med Ismaninger Str. 22 81675 München Germany